Scientists have found an eco-friendly and simpler way to discover new drugs. They’ve created special compounds that can help treat serious diseases like cancer and infections. To achieve this, they’ve engineered common brewer’s yeast into a small, glowing “factory” that produces beneficial substances itself.<\/p>\n
Each yeast cell is specifically programmed to produce a particular peptide. If the process is successful, the cell glows. Using high-precision flow cytometry, scientists can rapidly select the best candidates. In just a few hours, it’s possible to filter hundreds of millions of peptides. This process is much faster than traditional phage or mRNA display technologies, which don’t even allow for real-time observation.<\/p>\n
Macrocyclic peptides are of interest in pharmaceutical research because they bind well to disease-causing proteins, are more stable, and, compared to traditional drugs, rarely cause side effects (Driggers et al., 2008; Linciano et al., 2025). Existing methods are often expensive, slow, and environmentally unfavorable. The new yeast-based platform allows for the selection of ideal peptides in real-time, directly from living cells.<\/p>\n
“We programmed yeast cells so that each one produces a fluorescent light when it generates a specific compound. This enabled us to rapidly and efficiently screen 100 million peptides,” says lead specialist Sarah Linciano (Phys.org, 2025).<\/p>\n
The scientists confirmed their findings using X-ray crystallography. This means the selected peptides exhibit “excellent binding properties” and “outstanding affinity and selectivity” towards their targets (Linciano et al., 2025). This technology could significantly accelerate the drug discovery process, especially against chronic and incurable diseases. Therefore, it’s considered a biocompatible and sustainable path for drug discovery.<\/p>\n
References<\/p>\n
Linciano, S., Mazzocato, Y., Romanyuk, Z., et al. (2025). Screening macrocyclic peptide libraries by yeast display allows control of selection process and affinity ranking. Nature Communications<\/a>, 16, 5367.<\/p>\n